Lichenoid Reactions From CD-2 and CD-3 Carola Lidén, Department of Occupational Dermatology, Karolinska Hospital, Stockholm, Sweden.

The paper gives a report on the Karolinska Hospital Information System in three parts.In part I, the information problems in health care delivery are discussed and the approach to systems design at the Karolinska Hospital is reported, contrasted, with the traditional approach.In part II, the data base and the data processing system, named T1—J 5, are described.In part III, the applications of the data base and the data processing system are illustrated by a broad description of the contents and rise of the patient data base at the Karolinska Hospital.

Download Full-text

Drug Induced Lichenoid Reactions―A Literature Review

Indian Journal of Public Health Research & Development ◽

10.37506/v10/i12/2019/ijphrd/192392 ◽

2019 ◽

Vol 10 (12) ◽

Author(s):

G. Nishanth ◽

N. Aravindha Babu ◽

E. Rajesh ◽

K. M. K. Masthan

Keyword(s):

Literature Review ◽

Drug Induced ◽

Lichenoid Reactions

Download Full-text

Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

Journal of Clinical Medicine ◽

10.3390/jcm10051040 ◽

2021 ◽

Vol 10 (5) ◽

pp. 1040

Author(s):

Jo L. W. Lambert ◽

Sofie De Schepper ◽

Reinhart Speeckaert

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Cutaneous Manifestations ◽

Cutaneous Infections ◽

Tnf Α ◽

Common Skin ◽

Receptor Blockers ◽

Infusion Reactions ◽

Inflammatory Bowel ◽

Lichenoid Reactions

The biologic era has greatly improved the treatment of Crohn’s disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. It is important to recognize these conditions as treatment-induced adverse reactions and adapt the treatment strategy accordingly. Some conditions can be treated topically while others require cessation or switch of the biological therapy. TNF-α antagonists have the highest rate adverse skin eruptions followed by ustekinumab and anti-integrin receptor blockers. In this review, we provide an overview of the most common skin eruptions which can be encountered in clinical practice when treating IBD (Inflammatory bowel disease) patients and propose a therapeutic approach for each condition.

Download Full-text